The Urgent Need for Innovative Treatments in Neuroinflammation and Neurodegeneration
Neuroinflammation and neurodegeneration are at the root of many debilitating conditions, affecting millions of Americans and placing a significant burden on healthcare systems. Emerging research highlights the critical role of chronic inflammation in diseases such as Alzheimer’s, Parkinson’s, multiple sclerosis, and traumatic brain injuries.
Recognizing the urgency of this challenge, major U.S. government agencies have prioritized the development of novel treatments. The National Institutes of Health (NIH) has launched multiple initiatives, including the BRAIN Initiative, which funds research to advance our understanding of brain disorders, and direct grants to study the mechanisms of neuroinflammation. Additionally, the FDA has accelerated approvals for treatments targeting neurodegenerative diseases, such as Leqembi for Alzheimer’s and Aqneursa for Niemann-Pick disease, signaling strong support for innovation in this field.
With increasing investment and scientific breakthroughs, the landscape of neuroinflammatory disease treatment is rapidly evolving, offering hope for millions in need of better solutions.
EicOsis is Advancing Breakthrough Therapies for Neuroinflammation and Healing
At EicOsis, we are pioneering a new class of safe and effective oral medicines designed to restore the body’s natural ability to regulate inflammation. Our approach targets soluble epoxide hydrolase (sEH), a key enzyme involved in neuroinflammatory processes, with the potential to improve outcomes in conditions linked to chronic inflammation and neurodegeneration.
We have completed three Phase 1 clinical trials demonstrating the safety, tolerance, and ideal pharmacokinetic profile of our potent sEH inhibitor, EC5026 in healthy volunteers. With these promising results, we are positioned to advance into efficacy trials in the coming year and are actively developing strategic partnerships to drive continued progress.
Learn how we are reshaping the future of neuroinflammatory disease treatment and unlocking new pathways to healing.
Additional Resources
Pain management has been identified as a priority health issue by several international and national organizations and the challenges of its pharmacologic treatment have been emphasized by international clinical societies and acknowledged by the FDA as part of their series of Patient-Focused Drug Development Initiatives. Learn more about the unmet needs of pain management:
- NIH Interagency Pain Research Coordinating Committee (IPRCC): The IPRCC is a Federal advisory committee created by the Department of Health and Human Services to enhance pain research efforts and advance the fundamental understanding of pain and improving pain-related treatment strategies. Learn more
- CDC Report: Prevalence of Chronic Pain and High-Impact Chronic Pain Among Adults — United States, 2016
- The Institute of Medicine (IOM) 2011 Report: Relieving Pain in America: A Blueprint for Transforming Prevention, Care, Education, and Research
- NIH Helping to End Addiction Long-term (HEAL) Initative: Launched in 2018 to speed scientific solutions for the national opioid public health crisis. Learn more
- FDA’s Statement on the agency’s accomplishments implementing SUPPORT Act authorities to address the opioid crisis. Learn more
